Pravastatin reduces marfan aortic dilation

Circulation

Volumn 124, Issue 11 SUPPL. 1, 2011, Pages

  McLoughlin, Darren ^a   McGuinness, Jonathan ^a   Byrne, John ^a   Terzo, Eloisa ^b   Huuskonen, Vilhelmiina ^b   McAllister, Hester ^b   Black, Alexander ^c   Kearney, Sinead ^c   Kay, Elaine ^a   Hill, Arnold D K ^a   Dietz, Harry C ^d   Redmond, J Mark ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aneurysm; aorta; pathology; remodeling; vessels

Indexed keywords

ELASTIN; FIBRILLIN 1; LOSARTAN; PRAVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA DISEASE; AORTA ROOT; AORTIC ROOT DILATION; ARTERIAL WALL THICKNESS; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HEART CATHETER; MALE; MARFAN SYNDROME; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROUGH ENDOPLASMIC RETICULUM; SMOOTH MUSCLE FIBER; STEREOLOGY; ULTRASTRUCTURE ANALYSIS AND ELECTRON MICROSCOPY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; AORTIC DISEASES; DILATATION, PATHOLOGIC; DISEASE MODELS, ANIMAL; ELASTIN; ENDOPLASMIC RETICULUM; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOSARTAN; MALE; MARFAN SYNDROME; MICE; MICE, MUTANT STRAINS; MUSCLE, SMOOTH, VASCULAR; PRAVASTATIN; TREATMENT OUTCOME; TUNICA MEDIA;

EID: 80052719936     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.012187     Document Type: Article

References (22)

1. Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. Circulation. 2005;111:e150-e157.
2. Bunton TE, Biery NJ, Myers L, Gayraud B, Ramirez F, Dietz HC. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res. 2001;88:37-43. (Pubitemid 32064080)
3. Judge DP, Biery NJ, Keene DR, Geubtner J, Myers L, Huso DL, Sakai LY, Dietz HC. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest. 2004; 114:172-181. (Pubitemid 39071622)
4. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33: 407-411. (Pubitemid 36278859)
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
6. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators Circulation. 1998;98:839-844. (Pubitemid 28397432)
7. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001; 103:926-933. (Pubitemid 32183796)
8. Yu Y, Ohmori K, Chen Y, Sato C, Kiyomoto H, Shinomiya K, Takeuchi H, Mizushige K, Kohno M. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol. 2004;44:904-913. (Pubitemid 39099592)
9. Radonic T, de Witte P, Baars MJ, Zwinderman AH, Mulder BJ, Groenink M. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial. Trials. 2010;11:3.
10. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117-121.
11. Mayhew TM. The new stereological methods for interpreting functional morphology from slices of cells and organs. Exp Physiol. 1991;76: 639-665.
12. Dockery P, Tang Y, Morais M, Vacca-Galloway LL. Neuron volume in the ventral horn in Wobbler mouse motoneuron disease: a light microscope stereological study. J Anat. 1997;191(Pt 1):89-98. (Pubitemid 27385106)
13. Ramirez F, Dietz HC. Fibrillin-rich microfibrils: Structural determinants of morphogenetic and homeostatic events. J Cell Physiol. 2007;213: 326-330. (Pubitemid 47509709)
14. Dean JC. Marfan syndrome: clinical diagnosis and management. Eur J Hum Genet. 2007;15:724-733. (Pubitemid 46969881)
15. Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, Gabrielson KL, Hausladen JM, Mecham RP, Judge DP, Dietz HC. TGFbeta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest. 2004;114:1586-1592. (Pubitemid 40385549)
16. Ramirez F, Dietz HC. Marfan syndrome: from molecular pathogenesis to clinical treatment. Curr Opin Genet Dev. 2007;17:252-258. (Pubitemid 46843550)
17. Pereira L, Lee SY, Gayraud B, Andrikopoulos K, Shapiro SD, Bunton T, Biery NJ, Dietz HC, Sakai LY, Ramirez F. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc Natl Acad Sci USA. 1999;96:3819-3823. (Pubitemid 29168994)
18. Johnson J, Carson K, Williams H, Karanam S, Newby A, Angelini G, George S, Jackson C. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation. 2005;111:1422-1430. (Pubitemid 40396809)
19. Kalela A, Laaksonen R, Lehtimaki T, Koivu TA, Hoyhtya M, Janatuinen T, Pollanen P, Vesalainen R, Saikku P, Knuuti J, Nikkari ST. Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. Am J Cardiol. 2001;88:173-175, A176. (Pubitemid 32607707)
20. Gelb MH, Brunsveld L, Hrycyna CA, Michaelis S, Tamanoi F, Van Voorhis WC, Waldmann H. Therapeutic intervention based on protein prenylation and associated modifications. Nat Chem Biol. 2006;2: 518-528. (Pubitemid 44413234)
21. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1,-2,-3, and-9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23:769-775. (Pubitemid 36566165)
22. Yang HH, Kim JM, Chum E, van Breemen C, Chung AW. Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome. J Thorac Cardiovasc Surg. 2010;140:305-312.e2.